
Opinion|Videos|October 31, 2024
Exploring Rapid-Acting Therapies in MDD: Pharmacodynamics and Treatment Evolution
Key Takeaways
Gus Alva, MD, DFAPA; Carmen Kosicek, MSN, PMHNP-BC; and Roger McIntyre, MD, FRCPC delve into FDA-approved rapid-acting treatments for MDD and TRD, focusing on the sigma-1 agonist and its pharmacodynamics. They explore treatment indications, the rapid onset of action, and how these innovations address unmet clinical needs and shift the treatment paradigm for newly diagnosed depression
Advertisement
Episodes in this series

Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Social Challenge of the Powerful Taking Care of the Poor: Columbus Day, Indigenous People’s Day, and More
2
Asynchronous ADHD Assessment: New Tools for Better Evaluation
3
Women Are Diagnosed With ADHD 5 Years Later Than Men
4
Early Dose Management and Up-Titration of Esketamine: ECNP Poster Data
5